Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Akcea and Ionis receive a $250 million upfront license fee, with up to $1.3 billion in milestones plus tiered double-digit royalties; Pfizer CSO Mikael…
'The data are a mixed bag, with the primary endpoint success offset by the failure to improve secondary measures of relevance to the patient population...…
SVB Leerink analyst Mani Foroohar suggested ANGPTL3 may not be as predictably effective as PCSK9 targeting; Ionis shares fell as much as 11% on the…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Ionis/Akcea licensed exclusive worldwide rights to AKCEA-ANGPTL3-LRx (later vupanorsen) to Pfizer for $250M upfront and up to $1.3 billion in development, regulatory and sales milestones, plus tiered royalties starting in the low- to high-teens. Pfizer terminated the collaboration in early 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Akcea Therapeutics / Ionis Pharmaceuticals (AKCEA-ANGPTL3-LRx license) (this deal) | 2019 | $1.3B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Pfizer Inc. deals · Cardiovascular deals